ArticleResearch square2025

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.

Tadashi Manabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.